Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | |||
Cons | - |
INDMoney rank | 7/8 | |||
Category,Subcateogry | Equity,Sector - Healthcare | |||
Fund Age | 12 Years | |||
Fund Size | 8081 Cr | |||
Min Investment | SIP ₹100 Lumpsum ₹5000 | |||
Expense Ratio | 0.91% | |||
Exit Load | 1% | |||
Benchmark Index | BSE Healthcare TR INR |
No of Holdings | 40 | |||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.43%) Divi's Laboratories Ltd (9.28%) Lupin Ltd (7.27%) Cipla Ltd (5.71%) Apollo Hospitals Enterprise Ltd (5.31%) | |||
No of Sectors | 1 | |||
Top 3 Sectors | Health (100%) | |||
Equity % | 99.46% | |||
Debt % | - | |||
P/E | 35.57 | |||
P/B | 5.87 | |||
Credit Quality | - | |||
Modified Duration | - | |||
YTM | - |
1-Month Return | 4.1% | |||
3-Month Return | -2.83% | |||
6-Month Return | -8.27% | |||
1-Year Return | 15.16% | |||
3-Year Return | 18.88% | |||
5-Year Return | 23.8% |
Sharpe | 0.81 | |||
Alpha | 0.5 | |||
Beta | 0.9 | |||
Standard Deviation | 15.85 | |||
Information Ratio | -0.21 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | |||
Managers | Sailesh Raj Bhan,Kinjal Desai |